OncoMatch

OncoMatch/Clinical Trials/NCT05997017

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Is NCT05997017 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies nab-sirolimus for endometrial cancer.

Phase 2RecruitingAadi Bioscience, Inc.NCT05997017Data as of May 2026

Treatment: nab-sirolimus — A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Endometrial Cancer

Biomarker criteria

Excluded: TSC1 inactivating alteration

Excluded: TSC2 inactivating alteration

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 1 prior line
Min 0 prior lines

Cannot have received: mtor inhibitor (nab-sirolimus)

Lab requirements

Blood counts

ANC ≥1.0 × 10^9/L (growth factor support allowed); Platelet count ≥100,000/mm3 (transfusion and/or growth factor support allowed); Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed)

Kidney function

creatinine clearance (CrCL) ≥30 mL/min based on Cockcroft-Gault

Liver function

Total bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome, then ≤3 × ULN); AST ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)

Adequate liver function: Total bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome, then ≤3 × ULN); AST ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases). Adequate renal function: creatinine clearance (CrCL) ≥30 mL/min based on Cockcroft-Gault. Adequate hematologic parameters: ANC ≥1.0 × 10^9/L (growth factor support allowed); Platelet count ≥100,000/mm3 (transfusion and/or growth factor support allowed); Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed).

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Michael Birrer, MD, PhD · Little Rock, Arkansas
  • Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
  • Women's Cancer Center of Nevada · Las Vegas, Nevada
  • Memorial Sloan Kettering Cancer Center · New York, New York
  • Levine Cancer Institute · Charlotte, North Carolina

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify